Syngene International, a global contract research, development and manufacturing organisation (CRDMO), has launched a novel protein production platform.
It uses a cell line and transposon-based technology, which has been in-licensed from ExcellGene — a Swiss biotech services company — and will aim to optimise production efficiency and precision.
Reducing time to market
The new platform accelerates enhanced protein production, enabling quicker preclinical and clinical development as well as product launches, thereby reducing time to market.
"By combining the cell line and transposon-based platform from ExcellGene with our proprietary processes, we will aim to accelerate development timelines and enhance the overall reliability and efficiency of the process,” said Vice President of Biopharmaceutical Development, Syngene International, Sridevi Khambhampaty.
The new platform streamlines clone selection and enhances operational productivity, according to Syngene.
It also supports a wide range of biomolecules including monoclonal antibodies, biosimilars, bispecifics, antibody-drug conjugates and other recombinant proteins — allowing integration with both perfusion and fed-batch manufacturing processes.
By combining this technology with Syngene’s existing capabilities, the company now offers a full range of end-to-end cell line development options.
